Wednesday 6-25-2014 Ohr Pharmaceutical Inc (OHRP)

Wednesday 6-25-2014 Ohr Pharmaceutical Inc (OHRP) $OHRP opened at 7.50 hitting the high price of 7.71 and a day low of 6.86 with a total volume of 2,272,398. OHRP had a previous close of 7.74 and has been seeing an average volume of 628,515.

Overall Average: 88% Sell

Recent stock forum discussions about OHRP http://investorshangout.com/search?q=OHRP&...mp;yt0=Go!

Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig
at The Street - Tue Jun 24, 11:07AM CDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly. (full story)

Ohr Pharmaceutical (OHRP) Soars: Stock Adds 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 8:18AM CDT
Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise by almost 17% on the day. (full story)

Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD
GlobeNewswire - Tue Jun 24, 6:00AM CDT
-- Patients treated with Squalamine eye drops plus Lucentis PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN (full story)

Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD
GlobeNewswire - Mon Jun 23, 3:30PM CDT
Webcast to be Held on Tuesday, June 24 at 8:30am Eastern (full story)

5 Stocks Setting Up to Break Out
at The Street - Mon Jun 23, 8:37AM CDT
These stocks look poised to break out and trade higher from current level.s (full story)

Onconova Therapeutics (ONTX) in Focus: Stock Up 14.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:46AM CDT
Onconova Therapeutics (ONTX) was a big mover last session, with shares rising just over 14% on the day. (full story)

Recro Pharma (REPH) in Focus: Stock Gains 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:25AM CDT
Recro Pharma (REPH) was a big mover last session, with shares rising over 6% on the day. (full story)

Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter
Marketwire - Thu Jun 05, 1:48AM CDT
Vista Partners ("Vista" published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. (full story)

Ohr Pharmaceutical Announces Closing of SKS Ocular Acquisition; Strengthens Executive Management Team
GlobeNewswire - Mon Jun 02, 8:35AM CDT
Jason Slakter, MD Appointed Chief Medical Officer (full story)

DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer
GlobeNewswire - Tue May 27, 7:01AM CDT
DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) and Cold Spring Harbor Laboratory, today announced the validation of Trodusquemine (MSI-1436) as a therapeutic candidate for HER2-positive breast cancer. Trodusquemine is the Company's inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B). The results were published online on May 20, 2014 in Nature Chemical Biology. (full story)

Ohr Pharmaceutical Announces Agreement to Acquire Technology Assets of SKS Ocular
GlobeNewswire - Thu May 15, 3:01PM CDT
-- Transaction Expands Ohr's Pipeline to Include Multiple New Drug Candidates in Ophthalmology (full story)

Long Island Capital Alliance Announces Highly Successful Biotech Capital Forum
Marketwire - Thu May 15, 8:02AM CDT
The Long Island Capital Alliance ("LICA" , the leading non-profit capital formation and business development organization serving regional companies, today announced the successful completion of its Biotech Capital Forum held on Friday, May 9, 2014. Held in collaboration with North Shore-LIJ Health System's Feinstein Institute for Medical Research and Cold Spring Harbor Laboratory, the event provided an opportunity to bring together capital providers, entrepreneurs, industry executives and businesses seeking capital, as well as to hear a panel of industry experts discuss financing alternatives for biotechnology companies on Long Island which was moderated by LICA Board Member Michael A. Lane. (full story)

Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema
GlobeNewswire - Fri May 09, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema (DME). (full story)

Regeneron-Avalanche Partnership Underscores Ohr Pharma's Eye-Disease Isolation
at The Street - Mon May 05, 8:54AM CDT
The Regeneron-Avalanche partnership and the hedge funds investment in the latter is more indirect evidence that Ohr Pharmaceuticals and its AMD eye drop Squalamine are not taken seriously. (full story)

Vista Partners Publishes May 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri May 02, 8:01AM CDT
Vista Partners ("Vista" published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Adtech, Biotechnology, Travel, Energy, Healthcare, Kentucky Derby, Gold, Natural Resources & More. (full story)

5 Stocks Under $10 Set to Soar
at The Street - Thu May 01, 1:30PM CDT
These under-$10 stocks look ready to trade higher from current levels. (full story)

Ohr Pharmaceutical concludes patient enrollment in the US in Phase II clinical trial of Squalamine Eye Drops in Wet-AMD
M2 - Wed Apr 30, 3:52AM CDT
Pharmaceutical company Ohr Pharmaceutical (NasdaqCM:OHRP) disclosed on Tuesday the completion of patient enrollment as part of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration (wet-AMD). (full story)

Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD
GlobeNewswire - Tue Apr 29, 4:00AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has completed the enrollment of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration ("wet-AMD" . The study has enrolled a total of 142 patients, and the Company expects to announce interim data on the first 60 patients completing the protocol in June this year. Final data are expected in the first calendar quarter of 2015. (full story)

Fight! DJIA and S&P vs. Nasdaq and Russell 2000
at The Street - Tue Mar 25, 3:44PM CDT
Tuesday was another wild ride in the markets. Nothing seems to be able to keep the DJIA and S&P down. The Nasdaq and Russell 2000 are another story. (full story)

Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy (full story)